LG Chem launched Taurokit 2% injection in Korea, enhancing infection prevention, safety, efficiency, and supply reliability through UK Chemiphar collaboration.
LG Chem announced on Thursday the official launch of Taurokit 2% solution for injection in South Korea. The product, developed by UK-based Chemiphar, is an advanced antimicrobial drug formulated to help prevent surgical site infections, particularly in complex procedures such as artificial joint replacement. Recently approved for clinical use, Taurokit will be distributed exclusively in the Korean market under LG Chem’s management.
The core active substance of Taurokit is taurolidine, which is synthesized from taurine. Taurolidine demonstrates strong antimicrobial activity by binding to biological cell walls and generating active antimicrobial derivatives, thereby effectively reducing the risk of bacterial contamination during invasive procedures. According to LG Chem, this solution can be applied as an irrigation agent during surgeries to prevent infection in a range of clinical situations, including peritonitis, damage to bone or soft tissue, and pleural abscess operations.
One of the key highlights of the product is its fully domestic production system. LG Chem pointed out that every stage—from the raw material preparation to the final packaging—is carried out within South Korea. This ensures a stable and reliable supply chain in a medical market that frequently faces product shortages or delays due to international sourcing challenges.
In addition to its pharmaceutical properties, Taurokit introduces improvements in usability. The packaging has been redesigned, simplifying the sealing process from three steps down to just two. This change allows faster and safer preparation of the solution, which in turn helps medical professionals save valuable time in surgical environments where efficiency and accuracy are critical.
LG Chem emphasized that Taurokit not only strengthens safety standards but also improves operational efficiency for healthcare workers. By reducing infection risks and offering easier preparation, the product enables doctors and nurses to concentrate more effectively on the surgical procedures themselves rather than on preparatory tasks.
UK Chemiphar, which partnered with LG Chem for this launch, confirmed its commitment to ensuring swift and reliable supply of Taurokit across hospitals nationwide. Both companies expressed confidence that the drug would make a meaningful impact in preventing postoperative infections and supporting better patient outcomes.
LG Chem further explained that the launch was the result of extensive research and careful analysis of demand in the medical field. The company has been actively studying unmet needs in surgical infection prevention and believes Taurokit answers many of these challenges. Looking forward, LG Chem plans to actively promote the product’s unique advantages and strengthen collaboration with UK Chemiphar to expand its adoption across clinical settings.
With this introduction, LG Chem positions itself as a stronger player in the antimicrobial solutions market, while also reinforcing its dedication to innovation and patient safety.
